Structure/Class |
- Similar to TCA/Imipramine
|
Pharmacodynamics |
- Similar to phenytoin
- Na+ channel blockade. Inhibits repetitive high frequency neuronal firing.
- Also may potentiate K+ channel, causing hyperpolarization.
|
Absorption/administration |
- PO
- Peak levels occur at 6 hours
|
Distribution |
- Distributes slowly.
- Vd = 1L/kg,
- It is 70% bound to plasma proteins but there is no displacement of other drugs.
|
Metabolism |
- Completely metabolized hepatically to carbamazepine 10,11 epoxide (it has anti-convulsant activity)
- Strong inducer of hepatic enzymes. May induce its own metabolism and may require frequent dose changes in the first few weeks of treatment.
|
Excretion |
- Renal
|
Indications |
- GTCS
- Trigeminal neuralgia
- Mania
|
Contraindications |
|
Special precautions |
|
Interactions |
- Strong enzyme inducer and may also induce its own metabolism.
- Other inducers, e.g. phenytoin/phenobarbital may decrease its level.
- Other inhibitors (e.g. valproate) may increase its levels.
|
Adverse events |
- Side effects as follows:
- CNS (most common) – diplopia and ataxia. Mild drowsiness.
- GIT upset
- Idiosyncratic à blood dyscrasias and aplastic anaemia.
- Rash
|
Dosing/administration |
|
Toxicology |
|
Withdrawal syndrome |
|
Special notes |
|